Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research7/8/2026Positive
BVS
Bioventus IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$778.42M
P/E Ratio
28.73
EPS
$0.40
Beta
0.65
52W High
$12.23
52W Low
$5.81
50-Day MA
$9.64
200-Day MA
$8.34
Dividend Yield
—
Profit Margin
4.94%
Forward P/E
13.51
PEG Ratio
1.35
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Fundamentals
| Revenue (TTM) | $576.30M |
| Gross Profit (TTM) | $395.87M |
| EBITDA | $80.90M |
| Operating Margin | 6.73% |
| Return on Equity | 16.50% |
| Return on Assets | 5.61% |
| Revenue/Share (TTM) | $8.61 |
| Book Value | $2.79 |
| Price-to-Book | 3.76 |
| Price-to-Sales (TTM) | 1.35 |
| EV/Revenue | 1.642 |
| EV/EBITDA | 9.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 6.60% |
| Shares Outstanding | $67.75M |
| Float | $33.31M |
| % Insiders | 11.75% |
| % Institutions | 78.28% |
Historical Volatility
HV 10-Day
71.05%
HV 20-Day
60.85%
HV 30-Day
61.12%
HV 60-Day
61.21%
HV Rank
76.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($14.80 target)
2
Strong Buy3
BuyLatest News
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research7/8/2026Positive
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments.
Seeking Alpha7/7/2026Positive
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research7/7/2026Positive
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire7/3/2026Neutral
3 Top Breakout Stocks to Snap Up for Big Upside in July 2026
FA, BVS and OOMA emerged as July breakout stock picks after meeting momentum and price-based screens designed to spot potential upside.
Zacks Investment Research7/2/2026Positive
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research6/25/2026Positive
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research6/9/2026Positive
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS)
The heavy selling pressure might have exhausted for Bioventus (BVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research6/2/2026Negative
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026, at 4:00 p.m. ET.
GlobeNewsWire6/2/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026